Trial of SAGE-217 in Patients with Major Depressive Disorder
Trial of SAGE-217 in Patients with Major Depressive Disorder
About this item
Full title
Trial of SAGE-217 in Patients with Major Depressive Disorder
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2019-09, Vol.381 (10), p.903-911
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with major depression were treated with an oral γ-aminobutyric acid type A–receptor modulator for 14 days. At day 15, patients who received the drug had a greater reduction in depressive symptoms than patients who received placebo. Headache was the most common adverse event.
Alternative Titles
Full title
Trial of SAGE-217 in Patients with Major Depressive Disorder
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2285105493
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2285105493
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1815981
